Experienced in Plagiocephaly

Dr. Brendan H. Lee

Texas Childrens Physician Group
Austin, TX
Experienced
in Plagiocephaly
Specialties:Medical Genetics | Pediatrics
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Brendan Lee is a Medical Genetics specialist and a Pediatrics provider in Austin, Texas. Dr. Lee and is rated as an Experienced provider by MediFind in the treatment of Plagiocephaly. His top areas of expertise are Osteogenesis Imperfecta, Argininosuccinic Aciduria, Urea Cycle Disorders (UCD), and Spondyloepimetaphyseal Dysplasia Strudwick Type. Dr. Lee is currently accepting new patients.

His clinical research consists of co-authoring 269 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Plagiocephaly.

Specialties
Medical Genetics
Pediatrics
Licenses
Pediatrics in TX
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Community Health
  •  Friday Health
  •  Humana

Locations

TEXAS CHILDRENS PHYSICIAN GROUP
8611 N Mopac Expy, Austin, TX 78759
832-824-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)
A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Phase: Phase 3
Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD)
Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD)
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Dietary supplement
Study Phase: Not Applicable
View 2 Less Clinical Trials

3 Total Publications

Enteral arginase II provides ornithine for citrulline synthesis.
Enteral arginase II provides ornithine for citrulline synthesis.
Journal: American journal of physiology. Endocrinology and metabolism
Published: October 28, 2010

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile